Detalhe da pesquisa
1.
Impact of pretransplant minimal residual disease in patients with multiple myeloma and a very good partial response or better receiving autologous hematopoietic stem cell transplantation.
Cancer
; 130(9): 1663-1672, 2024 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38127583
2.
Impact of revised International Staging System 2 risk stratification on outcomes of patients with multiple myeloma receiving autologous haematopoietic stem cell transplantation.
Br J Haematol
; 204(5): 1944-1952, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38448009
3.
Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis.
N Engl J Med
; 385(1): 46-58, 2021 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34192431
4.
Impact of prior lenalidomide or proteasome inhibitor exposure on the effectiveness of ixazomib-lenalidomide-dexamethasone for relapsed/refractory multiple myeloma: A pooled analysis from the INSURE study.
Eur J Haematol
; 2024 Apr 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-38654611
5.
In-class transition from bortezomib-based therapy to IRd is an effective approach in newly diagnosed multiple myeloma.
Future Oncol
; 20(3): 131-143, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-37807952
6.
INSURE: a pooled analysis of ixazomib-lenalidomide-dexamethasone for relapsed/refractory myeloma in routine practice.
Future Oncol
; 20(14): 935-950, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38197267
7.
Single-agent belantamab mafodotin in patients with relapsed/refractory multiple myeloma: Final analysis of the DREAMM-2 trial.
Cancer
; 129(23): 3746-3760, 2023 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37622738
8.
Outcomes of young adults (aged ≤ 40 years) with newly diagnosed multiple myeloma after up-front autologous stem cell transplant.
Br J Haematol
; 202(4): 866-873, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37376789
9.
Systemic Light Chain Amyloidosis, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw
; 21(1): 67-81, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36652935
10.
Multiple Myeloma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw
; 21(12): 1281-1301, 2023 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-38081133
11.
Single-agent lenalidomide maintenance after upfront autologous stem cell transplant for newly diagnosed multiple myeloma: The MD Anderson experience.
Am J Hematol
; 98(10): 1571-1578, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37461327
12.
Activating KRAS, NRAS, and BRAF mutants enhance proteasome capacity and reduce endoplasmic reticulum stress in multiple myeloma.
Proc Natl Acad Sci U S A
; 117(33): 20004-20014, 2020 08 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-32747568
13.
Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA.
Blood
; 136(1): 71-80, 2020 07 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-32244252
14.
Health-related quality of life in patients with light chain amyloidosis treated with bortezomib, cyclophosphamide, and dexamethasone ± daratumumab: Results from the ANDROMEDA study.
Am J Hematol
; 97(6): 719-730, 2022 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35293006
15.
Quantitation of navtemadlin in human plasma and brain tissue by liquid chromatography-tandem mass spectrometry.
Biomed Chromatogr
; 36(11): e5467, 2022 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-35895384
16.
Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 study.
Cancer
; 127(22): 4198-4212, 2021 11 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34314018
17.
Effect of initial treatment on health-related quality of life in patients with newly diagnosed multiple myeloma without immediate stem cell transplant intent: results from the Connect® MM Registry.
Br J Haematol
; 193(1): 93-100, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33118614
18.
The survival impact of CKS1B gains or amplification is dependent on the background karyotype and TP53 deletion status in patients with myeloma.
Mod Pathol
; 34(2): 327-335, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-32908255
19.
Ubiquitin-activating enzyme inhibition induces an unfolded protein response and overcomes drug resistance in myeloma.
Blood
; 133(14): 1572-1584, 2019 04 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30737236
20.
Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the US.
Ann Hematol
; 100(9): 2325-2337, 2021 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-33970288